Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Novartis Pharmaceuticals Corporation
Description:
Over 73 million adults in the United States have
hypercholesterolemia and are at elevated risk for atherosclerotic
cardiovascular disease. Low-density lipoprotein cholesterol (LDL-C)
is a primary mediator of the development of heart disease and plays
a key role in determining cardiovascular risk and overall health
management. Early and aggressive lowering of LDL-C reduces the risk
of atherosclerotic cardiovascular disease (ASCVD) events in patients
with hypercholesterolemia, and every 1.0 mmol/L reduction in LDL-C
is estimated to lead to ~20% reduction in the relative risk of major
cardiovascular events. Many patients do not tolerate statin-based
treatment, and some patients, including those with pre-existing
ASCVD or severe hypercholesterolemia, do not reach recommended LDL-C
treatment targets despite intensive statin therapy. Fortunately for
patients with high LDL-C, several new treatments have recently
become available as an adjunct or instead of statin therapies. These
options, including agents that inhibit production of PCSK9, have
shown improved efficacy and safety, offering patients the potential
for improved outcomes and quality of life. With so many new options
available, it is critical that physician medical directors, payers,
cardiologists, pharmacy directors, pharmacists, nurse case managers,
and other HCPs are updated on the comparisons among safety,
efficacy, and administration data on these options, possible
strategies for implementing them into the treatment paradigm, and
key points that managed care professionals need to know, which will
ultimately improve both clinical and economic outcomes.
Upon completion of this
activity, participants will be able to:
-
Examine the pathophysiology of long-term exposure to elevated
LDL-C levels and the role of lipoprotein(a) as a risk factor for
atherosclerotic cardiovascular disease (ASCVD)
-
Assess the importance of lipoprotein(a) screening in ASCVD
management
-
Evaluate the latest clinical evidence, mechanisms of action, and
cardiovascular outcomes of current PCSK9-targeting agents for
LDL-C reduction in primary hyperlipidemia
-
Analyze the evolving role of siRNA-based inhibition of PCSK9 as
an adjunct to diet and statin therapy for patients at an
increased risk of heart disease
-
Implement managed care strategies to integrate evidence-based
use of PCSK9-modulating therapies while controlling healthcare
resource utilization
Faculty:
Michael Miller, MD, FACC, FAHA
Cardiologist and Professor of Medicine
University of Pennsylvania
Chief of Medicine
Corporal Michael J Crescenz VA Medical Center
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Miller has no relevant financial relationship with an ineligible
company to disclose.
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |